Lamotrigine and Idiopathic Intracranial Hypertension
Lamotrigine is safe to continue or initiate in patients with idiopathic intracranial hypertension (IIH), as it is not associated with drug-induced intracranial hypertension and does not appear in any established risk categories for medications that exacerbate or cause IIH.
Evidence Base for Drug-Induced Intracranial Hypertension
A comprehensive systematic review of all published cases of drug-induced intracranial hypertension (DIIH) from 1900 to 2019 identified 259 verifiable cases and stratified medications into five risk categories based on strength of association 1.
Lamotrigine does not appear in any of the five risk categories (from weakly associated Category I to strongly associated Category V), indicating no established causal relationship with intracranial hypertension 1.
The medications most strongly associated with DIIH (Categories IV and V) include vitamin A derivatives, tetracycline-class antibiotics, recombinant growth hormone, and lithium 1.
Moderately associated medications (Category III) include corticosteroids 1.
Weakly associated medications (Categories I and II) include cyclosporine, progestin-only contraceptives, combined oral contraceptives, fluoroquinolones, divalproic acid (notably, another antiepileptic), and several other agents 1.
Clinical Implications for IIH Management
When selecting medications for patients with IIH—particularly for headache prophylaxis—avoid drugs that promote weight gain (beta-blockers, tricyclic antidepressants, sodium valproate, pizotifen, flunarizine) or worsen depression (beta-blockers, topiramate, flunarizine), as these can complicate IIH management 2.
Lamotrigine's absence from the weight-gain category and its neutral profile regarding intracranial pressure make it a reasonable choice when antiepileptic therapy is indicated for comorbid conditions such as epilepsy or bipolar disorder in IIH patients 1.
Approximately 68% of IIH patients exhibit migrainous headache features, and migraine preventatives should be started early (requiring 3–4 months for maximal effect) 2, 3.
For migraine prophylaxis in IIH, weight-neutral options such as candesartan or venlafaxine are preferred 2, 3.
Common Pitfalls to Avoid
Do not confuse lamotrigine with other antiepileptic drugs that carry specific risks in IIH: topiramate (which is actually used therapeutically in IIH for its carbonic anhydrase inhibition and appetite suppression but carries risks of depression and cognitive slowing) and divalproic acid/sodium valproate (which promotes weight gain and appears in the weakly associated DIIH category) 2, 1.
When prescribing any medication to IIH patients, systematically review the patient's complete medication list to identify and eliminate drugs in DIIH risk categories, particularly if visual deterioration or worsening papilledema occurs 1.
Remember that acetazolamide does not relieve headache when used as monotherapy and should be prescribed only for visual protection, not for headache control 3, 4.